Revance Therapeutics Inc
NASDAQ:RVNC

Watchlist Manager
Revance Therapeutics Inc Logo
Revance Therapeutics Inc
NASDAQ:RVNC
Watchlist
Price: 3.65 USD Market Closed
Market Cap: 381m USD

Net Margin
Revance Therapeutics Inc

-74.7%
Current
-231%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-74.7%
=
Net Income
-184.4m
/
Revenue
247m

Net Margin Across Competitors

No Stocks Found

Revance Therapeutics Inc
Glance View

Market Cap
382.9m USD
Industry
Pharmaceuticals

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 495 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The firm is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. The company offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

RVNC Intrinsic Value
5.87 USD
Undervaluation 38%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-74.7%
=
Net Income
-184.4m
/
Revenue
247m
What is the Net Margin of Revance Therapeutics Inc?

Based on Revance Therapeutics Inc's most recent financial statements, the company has Net Margin of -74.7%.

Back to Top